AstraZeneca agrees to invest in Summit as AstraZeneca stock costs EUR 139.63
Published on 10/03/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 28, 2026, AstraZeneca announced an agreement to invest $2 billion in Summit Therapeutics, according to an AstraZeneca release. At 10:58 a.m. CEST on October 3, 2026, AstraZeneca stock stood at EUR 139.63 in weekend trading at Lang & Schwarz, unchanged from the EUR 139.63 close of the last Xetra trading day at Lang & Schwarz on October 2, 2026.
Weekend trading
The Lang & Schwarz bid was EUR 139.10 and the ask was EUR 140.15 at 10:58 a.m. CEST on October 3, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Last Xetra trading day
The reference close at Lang & Schwarz was EUR 139.63 on October 2, 2026. The current weekend-trading price therefore showed no change against that reference.
Investment and clinical collaboration
AstraZeneca said Summit will receive the $2 billion equity investment in newly issued preferred shares convertible into common stock. Following completion, the investment is expected to give AstraZeneca rights equivalent to approximately 12.00 percent of Summit’s outstanding common stock, or approximately 10.60 percent on a fully diluted basis. Closing was anticipated within one week, subject to customary regulatory clearances, according to the company release.
The companies also agreed to evaluate Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers and said they intend to initiate trials imminently. A separate non-binding memorandum outlines a potential broader development program combining ivonescimab with additional AstraZeneca antibody-drug conjugates. Each company is to retain development and commercial rights to its respective medicines, the release said.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
